Biological Factors – Page 2

Samsung Biologics Achieves Record Revenue and Secures Largest Contract to Date

3 months ago talkbio0Tagged Biological Factors, Biosimilars, CDMO, Contract agreement, Drug Industry, Largest, Revenue, Samsung

Samsung Biologics, Record Revenue, Largest Contract, Biosimilars, CDMO, Pharmaceutical Industry

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

3 months ago talkbio0Tagged Antibody-Drug Conjugates, Bio Campus II, Biological Factors, Capacity, CDMO, Contract agreement, development aspects, digital transformation, expansion, Manufacturing Organization, Plants, Samsung, Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)

Key Presentations at JPM25: AbbVie, UCB, WuXi Biologics Highlight Industry Trends

3 months ago talkbio0Tagged AbbVie, Biological Factors, biotech, healthcare innovation, J.P. Morgan Healthcare, JPM25, trends qualifier, UCB, WuXi

JPM25, J.P. Morgan Healthcare Conference, AbbVie, UCB, WuXi Biologics, Biotech Trends, Healthcare Innovation

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion to Strengthen Neuroscience Portfolio

3 months ago talkbio0Tagged Acquisition, Biological Factors, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Biopharmaceutical

WuXi Biologics Divests Irish Vaccine Facility to Merck for $500 Million Amid Strategic Shift

4 months ago talkbio0Tagged asset, Biological Factors, BIOSECURE, Dundalk, Facility (object), Ireland, Merck, regulatory, Sales - occupational activity, strategic shift, Vaccines, WuXi

WuXi Biologics, Merck, vaccine manufacturing facility, Dundalk, Ireland, asset sale, strategic shift, regulatory changes, Biosecure Act

Merck Acquires WuXi Biologics’ Irish Vaccine Facility in $500M Deal

4 months ago talkbio0Tagged Biological Factors, Facility (object), Ireland, Merck, pharmaceutical manufacturing, Vaccines, WuXi

Merck, WuXi Biologics, vaccine facility, Ireland, $500M deal, pharmaceutical manufacturing

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment

4 months ago talkbio0Tagged Biological Factors, Clinical stage finding, Dermatitis, Atopic, Ikena Oncology, IMG-007, Implantation procedure, Inmagene Biopharmaceuticals, Merger, Monoclonal Antibodies, Private Room, TNFRSF4 gene

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement

Strategic Roadmap for Biologics Manufacturing: Enhancing Efficiency and Flexibility

5 months ago talkbio0Tagged Biological Factors, biomanufacturing, bony process, Characterization, Continuous, Efficiency, Manufacturing, Modular Facilities, Pliability, Precision medicines, Regulatory Compliance, Strategic Roadmap, technology roadmap

Biologics manufacturing, Strategic roadmap, Process characterization, Flexibility and efficiency, Regulatory compliance, Biomanufacturing technology roadmap, Precision medicines, Modular facilities, Continuous manufacturing